---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088719"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2026-08-13T12:15:26+00:00"
generated_at: "2026-08-13T12:20:12.414818+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q3 FY2026 revenue up 16% to $2.0M; gross margin 59.9%, net loss $2.0M

## Summary
- Product revenue $2.0M, +16% YoY; product gross margin 59.9% vs 53.9% (record).
- New product orders $2.7M in Q3, +43% YoY; backlog $1.7M; FY2026 orders $11.2M.
- Net loss $2.0M ($0.23 basic, $0.28 diluted) vs $1.5M loss prior year; cash $2.0M.
- Received ISO 13485 certification; StereoCED platform expected by end FY2026 for research/IDE studies.
- Lead investor raised stake from 7.4% to 12.5% post-quarter; raised $1.0M via ATM on July 13.

## SEC filing metadata
- accession: 0001213900-26-088719
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2026-08-13T12:15:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390026088719/0001213900-26-088719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390026088719/ea0301787-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088719
- JSON: https://secwatch.observer/filing/0001213900-26-088719.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.